semaglutide oral fda approval Approves High-Dose 25mg Oral Obesity Drugs Edge Closer

According to the SmPC, these include: Nausea usually mild to moderate and often diminishing over time Vomiting and diarrhoea which can contribute to dehydration if not managed appropriately Abdominal pain and decreased appetite reflecting the medication's effect on gastric emptying and satiety signals Constipation affecting some patients, particularly those with reduced food and fluid intake Severe gastrointestinal symptoms can lead to dehydration, which may precipitate acute kidney injury in some patients

A: Yes, exceptionally well

But doctors say GLP-1s lend themselves well to this ultra-precise approach

The results last indefinitely as long as you continue to administer the injections as we prescribe